Table of Contents

1 Market Overview

• 1.1 Objectives of Research
  • 1.1.1 Definition
  • 1.1.2 Specifications
• 1.2 Market Segment
  • 1.2.1 by Type
    • 1.2.1.1 Prostacyclin and prostacyclin analogs
    • 1.2.1.2 Endothelin receptor antagonists (ERAs)
    • 1.2.1.3 Phosphodiesterase-5 (PDE-5) inhibitors
    • 1.2.1.4 Soluble guanylate cyclase (sGC) stimulators
  • 1.2.2 by Application
    • 1.2.2.1 Early-stage Drug Candidates (Phase I & Phase II)
    • 1.2.2.2 Late-stage Drug Candidates (Phase III & Registration Phase)
  • 1.2.3 by Regions

2 Industry Chain

• 2.1 Industry Chain Structure
• 2.2 Upstream
• 2.3 Market
  • 2.3.1 SWOT
  • 2.3.2 Dynamics

3 Environmental Analysis

• 3.1 Policy
• 3.2 Economic
• 3.3 Technology
• 3.4 Market Entry

4 Market Segmentation by Type

• 4.1 Market Size
  • 4.1.1 Prostacyclin and prostacyclin analogs Market, 2013-2018
  • 4.1.2 Endothelin receptor antagonists (ERAs) Market, 2013-2018
  • 4.1.3 Phosphodiesterase-5 (PDE-5) inhibitors Market, 2013-2018
  • 4.1.4 Soluble guanylate cyclase (sGC) stimulators Market, 2013-2018
• 4.2 Market Forecast
  • 4.2.1 Prostacyclin and prostacyclin analogs Market Forecast, 2019-2024
  • 4.2.2 Endothelin receptor antagonists (ERAs) Market Forecast, 2019-2024
  • 4.2.3 Phosphodiesterase-5 (PDE-5) inhibitors Market Forecast, 2019-2024
  • 4.2.4 Soluble guanylate cyclase (sGC) stimulators Market Forecast, 2019-2024

5 Market Segmentation by Application

• 5.1 Market Size
  • 5.1.1 Early-stage Drug Candidates (Phase I & Phase II) Market, 2013-2018
  • 5.1.2 Late-stage Drug Candidates (Phase III & Registration Phase) Market, 2013-2018
• 5.2 Market Forecast
  • 5.2.1 Early-stage Drug Candidates (Phase I & Phase II) Market Forecast, 2019-2024
  • 5.2.2 Late-stage Drug Candidates (Phase III & Registration Phase) Market Forecast, 2019-2024

6 Market Segmentation by Region

• 6.1 Market Size
  • 6.1.1 Asia-Pacific
    • 6.1.1.1 Asia-Pacific Market, 2012-2018
    • 6.1.1.2 Asia-Pacific Market by Type
    • 6.1.1.3 Asia-Pacific Market by Application
  • 6.1.2 North America
    • 6.1.2.1 North America Market, 2012-2018
    • 6.1.2.2 North America Market by Type
    • 6.1.2.3 North America Market by Application
  • 6.1.3 Europe
    • 6.1.3.1 Europe Market, 2012-2018
    • 6.1.3.2 Europe Market by Type
    • 6.1.3.3 Europe Market by Application
  • 6.1.4 South America
    • 6.1.4.1 South America Market, 2012-2018
    • 6.1.4.2 South America Market by Type
    • 6.1.4.3 South America Market by Application
  • 6.1.5 Middle East & Africa
    • 6.1.5.1 Middle East & Africa Market, 2012-2018
    • 6.1.5.2 Middle East & Africa Market by Type
    • 6.1.5.3 Middle East & Africa Market by Application
• 6.2 Market Forecast
  • 6.2.1 Asia-Pacific Market Forecast, 2019-2024
  • 6.2.2 North America Market Forecast, 2019-2024
  • 6.2.3 Europe Market Forecast, 2019-2024
  • 6.2.4 South America Market Forecast, 2019-2024
  • 6.2.5 Middle East & Africa Market Forecast, 2019-2024

7 Market Competitive

• 7.1 Global Market by Vendors
• 7.2 Market Concentration
• 7.3 Price & Factors
• 7.4 Marketing Channel

8 Major Vendors

• 8.1 Bayer
• 8.2 GSK
• 8.3 Arena
• 8.4 Actelion
• 8.5 Pfizer
• 8.6 United Therapeutics
• 8.7 Gilead Sciences
• 8.8 Lung Biotechnology PBC

9 Conclusion

Summary
The global Pulmonary Hypertension Drugs market will reach xxx Million USD in 2019 with CAGR xx% 2019-2024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.
Based on products type, the report describes major products type share of regional market. Products mentioned as follows:
Prostacyclin and prostacyclin analogs 
Endothelin receptor antagonists (ERAs) 
Phosphodiesterase-5 (PDE-5) inhibitors 
Soluble guanylate cyclase (sGC) stimulators
Leading vendors in the market are included based on profile, business performance etc. Vendors mentioned as follows:
Bayer 
GSK 
Arena 
Actelion 
Pfizer 
United Therapeutics 
Gilead Sciences 
Lung Biotechnology PBC
Based on Application, the report describes major application share of regional market. Application mentioned as follows:
Early-stage Drug Candidates (Phase I & Phase II)
Late-stage Drug Candidates (Phase III & Registration Phase)
Based on region, the report describes major regions market by products and application. Regions mentioned as follows:
Asia-Pacific
North America
Europe
South America
Middle East & Africa